Document is current
Any future updates will be listed below
-
Authors
Aghayan, Hamid Reza
Salimian, Fatemeh
Abedini, Atefeh
Fattah Ghazi, Samrand
Yunesian, Masud
Alavi-Moghadam, Sepideh
Makarem, Jalil
Majidzadeh-A, Keivan
Hatamkhani, Ali
Moghri, Maryam
Danesh, Abbas
Haddad-Marandi, Mohammad Reza
Sanati, Hassan
Abbasvandi, Fereshteh
Arjmand, Babak
Azimi, Pourya
Ghavamzadeh, Ardeshir
Sarrami-Forooshani, Ramin http://orcid.org/0000-0002-6999-9145
-
Clinical Trials BETA
Clinical trials referenced in this document:
irct20200621047859n4 at Iranian Registry of Clinical TrialsDocuments that mention this clinical trial
Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment
https://doi.org/10.1186/s13287-022-02953-6
- License Information
-
More Information
Article History
Received: 12 October 2021
Accepted: 4 June 2022
First Online: 28 July 2022
Declarations
:
: The final protocol of the project was approved by the institutional review board (IRB), under the supervision of the Medical Ethics Committee (IR.ACECR.IRCRC.REC.1399.009). Before the injection process, written informed consent was obtained from conscious patients or first of kin in unconscious patients.
: Not applicable.
: The authors declare that they have no competing interests.
